In both cases, significant tumor growth inhibition was observed (Fig. 1A and B), regardless of whether they were responsive (HOC106) or not (HOC107) to the first-generation dual PARP1/2 inhibitor olaparib (Supplementary Fig. S2). Here, PARP1 is linked to neoplasm.